[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].
Dontsov AV · 2017 · Klinicheskaia meditsina
Reported findings and study design
Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.
123 coronary-heart-disease patients with metabolic syndrome randomized to standard care (63) or adjunctive Dalargin (60); 84 additional CHD patients without metabolic syndrome formed a separate comparison group.
Dose, route and schedule
2 mg/day for ten days, with three courses during three months; route not specified in the indexed abstract.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Insulin change | −22.4% versus −6.5% | Dalargin + standard care versus standard care · 3 months · p<0.001 for Dalargin changes; p<0.05 for standard-care changes |
| TNF-α change | −55% versus −9.4% | Same randomized treatment groups · 3 months |
| IL-6 change | −56.3% versus −6.1% | Same groups · 3 months |
| Triglyceride change | −27.2% versus −17.4% | Same groups · 3 months |
| HDL cholesterol change | +17.4% versus +10.3% | Same groups · 3 months |
| Other Dalargin-arm changes | β-endorphin +32.6%; leptin −36.1%; cortisol −23.9%; LDL cholesterol −14% | Within-arm changes; not placebo-adjusted effects · 3 months · p<0.001 reported |
| Studied schedule | 2 mg/day for 10 days; 3 courses across 3 months | Reported study regimen |
Percentages are within-group changes. The abstract does not provide the interaction test, event rates or a cardiovascular risk reduction.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Biomarker outcomes do not establish fewer cardiovascular events. Blinding and allocation concealment are not described in the abstract.
- Indexed abstract reviewed; complete methods, sample-size details and adverse-event tables have not been assessed.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Citation and original source
Original source: Dontsov AV. [THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE]. Klinicheskaia meditsina 2017.
Molekul research summary: https://molekul.io/research/oct28-30303664. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry